Baillie Gifford & Co
VRTX icon

Baillie Gifford & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Baillie Gifford & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$135M Buy
272,561
+73,140
+37% +$32.4M 0.12% 118
2026
Q1 		$89M Sell
199,421
-1,667
-0.8% -$777K 0.09% 127
2025
Q4 		$91.2M Sell
201,088
-5,968
-3% -$2.57M 0.08% 132
2025
Q3 		$81.1M Sell
207,056
-5,423
-3% -$2.27M 0.06% 138
2025
Q2 		$94.6M Buy
212,479
+78,014
+58% +$36M 0.07% 129
2025
Q1 		$65.2M Sell
134,465
-15,373
-10% -$7.16M 0.06% 139
2024
Q4 		$60.3M Buy
149,838
+9,258
+7% +$4.29M 0.05% 138
2024
Q3 		$65.4M Sell
140,580
-27,036
-16% -$13M 0.05% 133
2024
Q2 		$78.6M Buy
+167,616
New +$72.8M 0.06% 123
2019
Q2 		– Sell
-424,845
Closed -$78.2M – 230
2019
Q1 		$78.2M Sell
424,845
-302,317
-42% -$55.8M 0.09% 107
2018
Q4 		$120M Buy
727,162
+132,435
+22% +$22.9M 0.16% 88
2018
Q3 		$115M Buy
594,727
+16,288
+3% +$2.9M 0.12% 89
2018
Q2 		$98.3M Buy
578,439
+31,744
+6% +$4.92M 0.11% 89
2018
Q1 		$89.1M Buy
546,695
+48,317
+10% +$7.89M 0.1% 88
2017
Q4 		$74.7M Buy
498,378
+6,547
+1% +$969K 0.09% 95
2017
Q3 		$74.8M Buy
491,831
+6,234
+1% +$938K 0.09% 92
2017
Q2 		$62.6M Buy
485,597
+31,483
+7% +$3.79M 0.08% 95
2017
Q1 		$49.7M Sell
454,114
-6,349
-1% -$559K 0.07% 96
2016
Q4 		$33.9M Buy
+460,463
New +$37.5M 0.06% 101

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baillie Gifford & Co's VRTX Position: Q2 2026 in Review

Baillie Gifford & Co increased its Vertex Pharmaceuticals (VRTX) stake by 37% in Q2 2026, buying an estimated $32.4M and bringing the position to 272,561 shares worth $135M. The position accounts for 0.12% of the portfolio, ranked #118.

Baillie Gifford & Co first reported a position in VRTX in Q4 2016 and has held it in 19 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Baillie Gifford & Co held 272,561 shares of Vertex Pharmaceuticals worth $135M as of Q2 2026.
  • Baillie Gifford & Co bought 73,140 Vertex Pharmaceuticals shares in Q2 2026, an estimated $32.4M.
  • Vertex Pharmaceuticals made up 0.12% of Baillie Gifford & Co's portfolio in Q2 2026, its #118 holding.
  • Baillie Gifford & Co first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 19 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.